Myelodysplastic Syndrome (MDS) Drugs Market Report 2026

The myelodysplastic syndrome (mds) drugs market size has grown strongly in recent years. It will grow from $3.7 billion in 2025 to $3.98 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing diagnosis rates of bone marrow disorders, availability of hypomethylating agents, expansion of oncology treatment centers, rising use of supportive transfusion therapies, improved disease awareness.

The myelodysplastic syndrome (mds) drugs market size is expected to see strong growth in the next few years. It will grow to $5.56 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing development of novel immunomodulatory drugs, rising adoption of precision medicine in hematology, expansion of clinical trial pipelines, growing focus on improving patient quality of life, increasing healthcare spending on rare diseases. Major trends in the forecast period include increasing use of targeted therapeutic regimens, rising adoption of oral and parenteral combination therapies, growing focus on personalized treatment approaches, expansion of supportive care therapies, enhanced monitoring of treatment outcomes.

The rising cases of myeloid leukemia are projected to boost the myelodysplastic syndrome (MDS) drug treatment market in the future. Myeloid leukemia is a cancer that starts in the bone marrow and impacts the cells that produce different types of blood cells. Myelodysplastic syndrome (MDS) drugs work to enhance bone marrow function by addressing the underlying cause of leukemia, helping to lower the risk of complications from low blood cell counts, decrease reliance on chemotherapy and transplants, and boost survival rates for those with myelodysplastic syndrome. For instance, in January 2023, according to the American Cancer Society, a U.S.-based nonprofit health organization, approximately 20,380 new cases and 11,310 deaths from acute myeloid leukemia (AML) were expected in adults during 2023. Thus, the growing incidence of myeloid leukemia is fueling demand in the myelodysplastic syndrome (MDS) drug market.

The increasing focus on research and development is poised to drive expansion in the myelodysplastic syndrome (MDS) drugs market. Research and development involves methodical scientific studies and experiments designed to discover, invent, and refine new therapeutic drugs and treatment strategies. This surge stems from deeper insights into MDS's molecular mechanisms and genetic alterations, allowing pharmaceutical firms and research organizations to pinpoint innovative treatment targets and craft targeted precision therapies for this diverse condition. The uptick in research and development fuels market growth by broadening the roster of therapies in clinical trials, resulting in fresh drug approvals that offer more choices for patients unresponsive to standard hypomethylating agents or needing different options. For instance, in February 2025, the National Center for Science and Engineering Statistics (NCSES), a U.S. government agency tracking data, reported that U.S. R&D spending climbed from $892 billion in 2022 to $940 billion in 2023, a rise of $48 billion. Thus, the rise in research and development is propelling the myelodysplastic syndrome (MDS) drugs market forward.

Major companies in the myelodysplastic syndrome (MDS) drugs market concentrate on creating innovative products like targeted therapies to enhance patient results, address particular customer requirements, and integrate with the broader ecosystem. Targeted therapy for myelodysplastic syndromes (MDS) uses drugs that precisely target genetic mutations or molecular defects in cancer cells, seeking to boost outcomes by selectively eliminating abnormal cells while sparing healthy tissue. For example, in October 2023, the U.S. Food and Drug Administration (FDA) approved Tibsovo (ivosidenib) for treating adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) who have an isocitrate dehydrogenase-1 (IDH1) mutation. The drug's efficacy for this indication was assessed in an open-label, single-arm, multicenter study involving 18 adult patients with relapsed or refractory MDS harboring an IDH1 mutation.

Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.

North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2025. The regions covered in the myelodysplastic syndrome (mds) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myelodysplastic syndrome (mds) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the myelodysplastic syndrome drugs market by increasing costs of imported active pharmaceutical ingredients, excipients, packaging materials, and sterile manufacturing equipment used in drug production. Pharmaceutical supply chains in North America and Europe are most affected due to dependence on imported components, while Asia-Pacific faces cost pressures on API exports. These tariffs are contributing to higher drug production costs and pricing pressures. However, they are also encouraging regional drug manufacturing, localized API sourcing, and long-term investments in domestic oncology drug production infrastructure.

The myelodysplastic syndrome (mds) drugs market research report is one of a series of new reports that provides myelodysplastic syndrome (mds) drugs market statistics, including myelodysplastic syndrome (mds) drugs industry global market size, regional shares, competitors with a myelodysplastic syndrome (mds) drugs market share, detailed myelodysplastic syndrome (mds) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the myelodysplastic syndrome (mds) drugs industry. This myelodysplastic syndrome (mds) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Myelodysplastic syndrome (MDS) medications treat myelodysplastic syndrome, a group of bone marrow disorders where the bone marrow doesn't produce sufficient healthy blood cells. They function by aiding in the restoration of normal gene activity in bone marrow cells and boosting red blood cell production.

The primary categories of myelodysplastic syndrome (MDS) medications include chemotherapy and immunomodulatory agents. Chemotherapy involves a form of cancer treatment that uses anti-cancer drugs to destroy malignant cells. These drugs are given via oral or intravenous routes to address conditions like refractory cytopenia with multilineage dysplasia, refractory anemia, and refractory anemia with ringed sideroblasts, serving various end users including hospitals, clinics, and ambulatory surgical centers.

The myelodysplastic syndrome (MDS) drugs market consists of sales of vidaza (azacitidine), dacogen (decitabine) and reblozyl (luspatercept-aamt). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.